| Metric | Q4'25 | Q1'26 | Change |
|---|---|---|---|
| Organic Sales Growth | 11.0% (vs 10.2% prior year) | 2.4% (vs strong Q1 2025 comp) | Collapsed 860 bps due to cyber incident |
| U.S. Organic Sales Growth | 9.6% ortho, 13% MedSurg in Q4 | 1.9% total | Dramatic deceleration across all segments |
| International Organic Sales Growth | 5.4% ortho, 10.9% MedSurg in Q4 | 3.9% total | Better relative performance vs U.S. |
| Adjusted EPS | $4.47 (+11.5% YoY) | $2.60 (-8.5% vs Q1 2025) | First negative EPS growth in years |
| Adjusted Gross Margin | 65.2% (+improvements despite tariffs) | 63.6% (-190 bps vs Q1 2025) | Lost manufacturing absorption hit hard |
| Adjusted Operating Margin | 30.2% (+100 bps in Q4) | 21.1% (-180 bps vs Q1 2025) | Massive deleverage from cyber disruption |
| Cash from Operations | $5B full year (+$820M vs 2024) | $581M Q1 | Normal seasonal outflows plus cyber impact |
| Mako Installations | Record Q4 worldwide | Best ever Q1 U.S. and international | Unstoppable momentum despite cyber chaos |
| Full Year Guidance | 8-9.5% organic growth, $14.90-15.10 EPS | 8-9.5% organic growth, $14.90-15.10 EPS (maintained) | Zero revision despite Q1 disaster |
| Pricing Impact | Modestly positive expected | 0.3% favorable | Minimal contribution vs expectations |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.